CAMBRIDGE, Mass., May 16, 2007 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will hold its Annual Meeting of Stockholders on June 13, 2007 at 8:30 am EDT at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA. Stockholders of record at the close of business on April 19, 2007 are entitled to vote at the Annual Meeting. Momenta has mailed a notice of the Annual Meeting and related proxy materials to stockholders of record on or about May 16, 2007.
About Momenta:
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company's most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Through its discovery program, the Company is seeking to discover and develop novel therapeutics, with an initial focus in oncology, by applying its technology to better understand sugars' functions in biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.